Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 6/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056170 | 0.81 | GRM2 (0.46) | ATMKIF11PRMT1CYP2C9GRM2 | |
| SCHEMBL3056174 | 0.81 | GRM2 (0.46) | ATMKIF11PRMT1CYP2C9GRM2 | |
| SCHEMBL31537531 | 0.81 | GRM2 (0.46) | ATMKIF11PRMT1CYP2C9GRM2 | |
| SCHEMBL14343479 | 0.77 | KIF11 (0.49) | KIF11 | |
| SCHEMBL1899105 | 0.74 | KIF11 (0.44) | KIF11CYP1A2CYP2D6 | |
| SCHEMBL14343478 | 0.73 | KIF11 (0.54) | KIF11 | |
| SCHEMBL3053147 | 0.71 | PRMT1 (0.43) | ATMPRMT1CYP2C9GRM2L3MBTL1 | |
| SCHEMBL13290637 | 0.71 | PRMT1 (0.43) | ATMPRMT1CYP2C9GRM2L3MBTL1 | |
| SCHEMBL7486608 | 0.70 | KIF11 (0.42) | KIF11CYP1A2CYP2D6 | |
| SCHEMBL232514 | 0.70 | KIF11 (0.42) | KIF11CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745392-B2 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | NITTO DENKO CORPORATION (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20070078078-A1 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| WO-2007038169-A2 | MULTI-VALENT GUANIDINIUM COMPOUNDS FOR MOLECULAR TRANSLOCATION ACROSS CELLULAR MEMBRANES AND EPITHELIAL TISSUES | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078078-A1 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | GLS, FABP2, GOLIM4 | ATM 4425/4885KIF11 3922/4885PRMT1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.